Skip to main content

Table 1 Mocetinostat improved left ventricular function in CHF

From: HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation

 

Heart rate (bpm)

Maximum pressure (mmHg)

End-diastolic pressure (mmHg)

Ejection fraction (%)

Cardiac output (μL/min)

LV dP/dt max (mmHg/s)

CHF + MOCE

243.7 ± 21.1

110.5 ± 12.1

9.4 ± 3.4a

42.1 ± 14.3

23,234 ± 12,996

5,573 ± 689a

CHF

235.8 ± 16.1

102.7 ± 12.3b

28.7 ± 6.2b

33.6 ± 8.1b

19,001 ± 6,082b

3,921 ± 816b

SHAM

261.1 ± 39.4

122.5 ± 13.8

7.2 ± 2.3

63.0 ± 10.2

40,162 ± 16,010

6,928 ± 1,090

  1. Hemodynamic parameters were measured in sham, CHF and CHF treated with Mocetinostat. Sham (n = 8), CHF (n = 10), CHF + MOCE (n = 8). Data are presented as mean ± SD.
  2. aCHF + MOCE vs CHF, P <0.01.
  3. bCHF vs. SHAM, P <0.01.
  4. CHF, congestive heart failure; LV dP/dtmax, peak rate of left ventricular pressure rise; MOCE, Mocetinostat.
Back to article page

Fibrogenesis & Tissue Repair

ISSN: 1755-1536

Contact us